|Podcasts|November 3, 2017

Alzheimer Disease: New Drugs in the Offing?

What medications are in the pipeline that may help slow or even prevent the development of Alzheimer disease?

Here, Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, talks briefly about the most promising drugs-and the role of the ADDF in helping to bring those drugs through clinical trials.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

Video

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Alzheimer Disease: New Drugs in the Offing?

Newsletter

Related Content

This Week on NeurologyLive® — December 8, 2025

NeurologyLive® Friday 5 — December 5, 2025

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD

Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease

Latest CME

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy